Abstract
Azole antifungal drug ketoconazole has recently been demonstrated as an inhibitor of a ligand-induced pregnane X receptor (PXR)-mediated transcriptional regulation of the CYP3A4 gene through disruption of PXR interaction with steroid receptor coactivator (SRC)-1. In contrast, other clotrimazole-derived antifungal agents are known as potent inducers of CYP3A4 through PXR. In the present study, we examined effects of azole antimycotics clotrimazole, ketoconazole, econazole, oxiconazole, miconazole, fluconazole, and itraconazole on PXR-mediated expression of CYP3A4. We investigated individual effects of the tested azoles as well as their action on rifampicin-induced PXR-mediated transactivation and expression of CYP3A4 in LS174T cell line and primary human hepatocytes, their interactions with PXR ligand-binding domain, and azole-mediated recruitment of SRC-1 to PXR. In addition, applying the pharmacodynamic approach and dose-response analysis, we aimed to describe the nature of potential interactions of tested azole antimycotics coadministered with a prototypical PXR ligand rifampicin in transactivation of CYP3A4 gene. We describe additive and antagonistic interactions of partial and full agonists of PXR nuclear receptor in the therapeutic group of azole antimycotics in rifampicin-mediated transactivation of CYP3A4. We show that oxiconazole is a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by rifampicin in a competitive manner. In addition, we show that activation of the CYP3A4 promoter is a complex process, which is not exclusively determined by azole-PXR interactions, and we suggest that the ability of some azoles to affect recruitment of SRC-1 to PXR modulates their net effects in transactivation of CYP3A4 both in the absence or presence of rifampicin.
Footnotes
-
This study was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic (Grant NR/9206-3 to P.P.).
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.107.018341.
-
ABBREVIATIONS: PXR, pregnane X receptor; DDI, drug-drug interaction; RXRα, retinoid X receptor α (9-cis retinoic acid receptor-α); RE, response element; SRC, steroid receptor coactivator; RT, reverse transcriptase; PCR, polymerase chain reaction; LBD, ligand-binding domain; FBS, fetal bovine serum; SR12813, tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; DMSO, dimethyl sulfoxide; ER, everted repeat; CAR, constitutive androstane receptor; HNF, hepatocyte nuclear factor; GR, glucocorticoid receptor; DR, direct repeat; RID, receptor-interacting domain; VDR, vitamin D receptor; CYP, cytochrome P450; GAL4, yeast transcriptional activator of galactose-metabolizing enzymes.
- Received August 16, 2007.
- Accepted November 7, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|